Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5718 in Cutaneous Lupus Erythematosus
2022-501523-24-00Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) comparing GS-5718 with Placebo (2 arms). Primary endpoint: Percent change from baseline in CLASI-A score at Week 12. Started Sep 2023; status: completed.
02
Drugs
edecesertib
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2022-501523-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501523-24-00.